Can statin therapy alter the natural history of bicuspid aortic valves?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Verma, Subodh ^a,b   Szmitko, Paul E ^c   Fedak, Paul W M ^b   Errett, Lee ^b   Latter, David A ^b   David, Tirone E ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE;

ANEURYSM; AORTA ROOT; AORTA STENOSIS; AORTA VALVE; AORTA VALVE REGURGITATION; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HEART DEVELOPMENT; HISTOLOGY; HUMAN; ISCHEMIC HEART DISEASE; MITRAL VALVE; MITRAL VALVE DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY;

EID: 19344367500     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01221.2004     Document Type: Editorial

References (22)

1. Antonini-Canterin F, Zuppiroli A, Popescu BA, Granata G, Cervesato E, Piazza R, Pavan D, and Nicolosi GL. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 92: 1479-1482, 2003.
2. Beppu S, Suzuki S, Matsuda H, Ohmori F, Nagata S, and Miyatake K. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valve. Am J Cardiol 71: 322-327, 1993.
3. Chan KL, Ghani M, Woodend K, and Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenially bicuspid aortic valve. Am J Cardiol 88: 690-693, 2001.
4. Cripe L, Andelfinger G, Martin LJ, Shooner K, and Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol 44: 138-143, 2004.
5. Ergin MA, Spielvogel D, Apaydin A, Lansman SL, McCullough JN, Galla JD, and Griepp RB. Surgical treatment of the dilated ascending aorta: when and how? Ann Thorac Surg 67: 1834-1839, 1999.
6. Fedak PWM, de Sa MP, Verma S, Nili N, Kazemian P, Butany J, Strauss BH, Weisel RD, and David TE. Vascular matrix remodelling in patients with bicuspid aortic valve malformation: Implications for aortic dilatation. J Thorac Cardiovasc Surg 126: 797-806, 2003.
7. Fedak PWM, Verma S, David TE, Leask RL, Weisel RD, and Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 106: 900-904, 2002.
8. Heart Protection Study Collaborative Group (HPSCG). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002.
9. Huntington K, Hunter AG, and Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 30: 1809-1812, 1997.
10. Lee TC, Zhao YD, Courtman DW, and Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation 101: 2345-2348, 2000.
11. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, and Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363: 2015-2021, 2004.
12. Mohler ER. Are atherosclerotic processes involved in aortic valve calcification? Lancet 356: 524-525, 2000.
13. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, and DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071-1080, 2004.
14. Nistri S, Sorbo MD, Marin M, Palisi M, Scognamiglio R, and Thiene G. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart 82: 19-22, 1999.
15. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104: 2205-2209, 2001.
16. Rajamannan NM and Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110: 1180-1182, 2004.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
18. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E; and Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003.
19. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, and O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359: 1125-1126, 2002.
20. Thompson RW and Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci 800: 157-174, 1996.
21. Ward C. Clinical significance of the bicuspid aortic valve. Heart 83: 81-85, 2000.
22. Zamrini E, McGwin G, and Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 23: 94-98, 2004.